Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-37247 · 1 trial · 1 indication
The average pain intensity over the past 24 hours on the NRS-11 will be collected daily by electronic diary.
| Arm | Type | Description |
|---|---|---|
| CEP-37247 | EXPERIMENTAL | - |
| Matching placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CEP-37247 | DRUG | 0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route. |
| Placebo | DRUG | Matching placebo vials will be filled with the buffered solution for CEP-37247. |
Inclusion Criteria: * Over the 4 days prior to the randomization visit, the patient has a mean score greater than or equal to 5 (of 10) for "Average Pain Over the Past 24 Hours" for the pain in the affected leg as assessed by the 11-Point Numerical Rating Scale (NRS-11) captured in the electronic d...
CEP-37247 is an investigational small molecule being developed for the treatment of sciatica, specifically lumbosacral radicular pain associated with disk herniation. It is administered by the transforaminal epidural route. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CEP-37247 is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker TEVA. The drug is an investigational small molecule intended for the treatment of sciatica and is currently in Phase 1 clinical trials.
CEP-37247 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug is being studied for the treatment of sciatica, specifically lumbosacral radicular pain associated with disk herniation.
CEP-37247 has one completed clinical trial, identified as NCT01240876. This Phase 1 study evaluated the safety and efficacy of CEP-37247, also known as placulumab, administered by the transforaminal epidural route in patients with lumbosacral radicular pain associated with disk herniation. The trial enrolled 98 participants in the United States and Australia.
Yes, CEP-37247 is also known as placulumab. In clinical trial NCT01240876, the study title refers to the drug as placulumab (CEP-37247), confirming that these names refer to the same investigational drug being developed for the treatment of sciatica.